Open-label phase II study of everolimus plus endocrine therapy in post-menopausal women with ER+, HER2-metastatic breast cancer (Chloe trial)

被引：0
|
作者：
Shien, T. [1 ]
Shimomura, A. [2 ]
Uemura, Y. [3 ]
Kato, H. [4 ]
Kitada, M. [5 ]
Kikawa, Y. [6 ]
Shiba, E. [7 ]
Yoshida, T. [8 ]
Morimoto, T. [9 ]
Toyama, T. [10 ]
Aihara, T. [11 ]
Mukai, H. [12 ]
机构：
[1] Okayama Univ Hosp, Breast & Endocrine Surg, Okayama, Japan
[2] Natl Canc Ctr, Breast & Med Oncol, Tokyo, Japan
[3] Tokyo Univ Hosp, Biostat, Clin Res Support Ctr, Tokyo, Japan
[4] Teine Keijinkai Hosp, Thorac Surg, Sapporo, Hokkaido, Japan
[5] Asahikawa Med Univ, Surg, Asahikawa, Hokkaido, Japan
[6] Gen Hosp, Kobe City Med Ctr, Breast Surg, Kobe, Hyogo, Japan
[7] Osaka Breast Clin, Surg, Osaka, Japan
[8] Kanagawa Canc Ctr, Breast & Endocrine Surg, Yokohama, Kanagawa, Japan
[9] Yao Municipal Hosp, Breast Surg, Osaka, Japan
[10] Nagoya City Univ, Grad Sch Med Sci, Breast Surg, Nagoya, Aichi, Japan
[11] Keimeikai Aihara Hosp, Surg, Osaka, Japan
[12] Natl Canc Ctr Hosp East, Breast & Med Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
313TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with ER/HER2-metastatic breast cancer (MBC)
    Llombart-Cussac, Antonio
    Bellet, Meritxell
    Zamora, Pilar
    Ruiz, Manuel
    Gligorov, Joseph
    Di Cosimo, Serena
    Schmid, Peter
    Dawood, Shaheenah
    Roche, Henri
    Marme, Frederic
    Aguirre, Elena
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer.
    Mayer, Erica L.
    Wander, Seth Andrew
    Regan, Meredith M.
    DeMichele, Angela
    Forero-Torres, Andres
    Rimawi, Mothaffar F.
    Ma, Cynthia X.
    Cristofanilli, Massimo
    Anders, Carey K.
    Bartlett, Cynthia Huang
    Winer, Eric P.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] EVALUATION OF AROMATASE INHIBITOR UTILIZATION AND FAILURE IN POST-MENOPAUSAL WOMEN WITH ADVANCED ER+/HER2-BREAST CANCER
    Landsman-Blumberg, P.
    Namjoshi, M.
    Thomson, E.
    Johnson, W.
    VALUE IN HEALTH, 2012, 15 (04) : A229 - A230
  • [24] Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2-metastatic breast cancer with an ESR1 mutation
    Goetz, Matthew
    Wander, Seth
    Bachelot, Thomas
    Batist, Gerald
    Cortes, Javier
    Cristofanilli, Massimo
    Curigliano, Giuseppe
    de Nonneville, Alexandre
    Yam, Einav Nili-Gal
    Jhaveri, Komal
    Ma, Cynthia
    Parsons, Heather
    Rugo, Hope
    Sammons, Sarah
    Stover, Daniel
    Twelves, Chris
    Bardia, Aditya
    Plourde, Paul V.
    Portman, David J.
    Damodaran, Senthil
    CANCER RESEARCH, 2024, 84 (09)
  • [25] The SMILE study: A phase 2 trial of onapristone in combination with fulvestrant for patients with ER+ and HER2-metastatic breast cancer after progression on endocrine therapy and CDK4/6 inhibitors
    Kamaraju, Sailaja
    Fowler, Amy
    Cheng, Chung Yee
    Chaudhary, Lubna N.
    Burfeind, John
    Retseck, Janet
    Tevaarwerk, Amye J.
    Burkard, Mark
    Paplomata, Elisavet
    Parkes, Amanda M.
    Jorns, Julie M.
    Tarima, Sergey
    Yee, Douglas
    Rui, Hallgeir
    Lange, Carol
    Sahmoud, Tarek
    Wisinski, Kari B.
    CANCER RESEARCH, 2022, 82 (04)
  • [26] OVERALL SURVIVAL IN POST-MENOPAUSAL WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH 1ST-LINE ENDOCRINE THERAPY VS. CHEMOTHERAPY
    Vekeman, F.
    Hao, Y.
    Cheng, W. Y.
    Fortier, J.
    Robitaille, M.
    Duh, M. S.
    VALUE IN HEALTH, 2015, 18 (03) : A194 - A195
  • [27] Evaluation of Aromatase Inhibitor failure and total healthcare expenditures among post-menopausal women with metastatic ER+/HER2-breast cancer in the US
    Namjoshi, M.
    Landsman-Blumberg, P.
    Thomson, E.
    Chu, B. C.
    CANCER RESEARCH, 2012, 72
  • [28] Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer
    Elias, Anthony D.
    Spoelstra, Nicole S.
    Staley, Alyse W.
    Sams, Sharon
    Crump, Lyndsey S.
    Vidal, Gregory A.
    Borges, Virginia F.
    Kabos, Peter
    Diamond, Jennifer R.
    Shagisultanova, Elena
    Afghahi, Anosheh
    Mayordomo, Jose
    McSpadden, Tessa
    Crawford, Gloria
    D'Alessandro, Angelo
    Zolman, Kathryn L.
    van Bokhoven, Adrie
    Zhuang, Yonghua
    Gallagher, Rosa I.
    Wulfkuhle, Julia D.
    Petricoin III, Emanuel F.
    Gao, Dexiang
    Richer, Jennifer K.
    NPJ BREAST CANCER, 2023, 9 (01)
  • [29] Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
    Anthony D. Elias
    Nicole S. Spoelstra
    Alyse W. Staley
    Sharon Sams
    Lyndsey S. Crump
    Gregory A. Vidal
    Virginia F. Borges
    Peter Kabos
    Jennifer R. Diamond
    Elena Shagisultanova
    Anosheh Afghahi
    Jose Mayordomo
    Tessa McSpadden
    Gloria Crawford
    Angelo D’Alessandro
    Kathryn L. Zolman
    Adrie van Bokhoven
    Yonghua Zhuang
    Rosa I. Gallagher
    Julia D. Wulfkuhle
    Emanuel F. Petricoin III
    Dexiang Gao
    Jennifer K. Richer
    npj Breast Cancer, 9
  • [30] Phase II trial of fulvestrant plus enzalutamide in ER+/Her2-advanced breast cancer
    Elias, Anthony D.
    Spoelsta, Nicole
    Vidal, Gregory A.
    Sams, Sharon
    Kabos, Peter
    Diamond, Jennifer R.
    Shagisultanova, Elena
    Afghahi, Anosheh
    Mayordomo, Jose
    McSpadden, Tessa
    Crawford, Gloria
    Carter, Lisa
    Zolman, Kathryn
    Armstead, Stephanie
    Winchester, Alyse
    Borges, Virginia
    Wulfkuhle, Julia
    Petricoin, Emanuel
    Gao, Dexiang
    Richer, Jennifer
    CANCER RESEARCH, 2021, 81 (04)
12345